July 13, 2019

There are a lot of direct to consumer ads on TV these days. There is a lot of cultural diversity in the patients portrayed, and that lends itself to the assumption that these medications have the same effects across all racial segments. When you look deeper into the studies you often find the number of minority participants to be quite small. This could make a difference when we focus in on CHF, as only one medication, Bidil, has ever had a study focused on treating CHF in African Americans.

This week Amber Satz, PharmD Candidate, LECOM School of Pharmacy, has an interesting review of the possibility that the claims of CHF protection from GLP-1 Agonists and SGLT-2 Inhibitors may be misleading.

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief